Drug intelligence / Profile preview

897222 210

Development stage: Preclinical
Lead developer: Beijing Yuanben Information Consulting
Modality: Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

897222 210 is a test serum being investigated for its efficacy in promoting epidermal cell renewal. It is applied topically and is currently undergoing evaluation in a double-blind, randomized, and controlled clinical study involving Chinese female participants. The study aims to assess its effects on skin health over a period of 23 consecutive days.

Beyond the preview

Go deeper on 897222 210.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 897222 210.

Explore the full profile